Empagliflozin PBS expansion will cover all HF patients
The listing will cover all patients with symptomatic heart failure across the ejection fraction spectrum.
The PBS listing for empagliflozin will soon be expanded to cover all patients with symptomatic heart failure regardless of ejection fraction.
From 1 November, doctors can issue PBS scripts for 10mg daily empagliflozin (Jardiance) for heart failure with left ventricular ejection fraction (LVEF) greater than 40% as an adjunct to standard therapy.
This includes patients with heart failure with preserved ejection fraction (HFpEF).
The updated listing was recommended by the PBAC in February, which noted the “high unmet clinical need for effective treatments” for a condition that affected an estimated half a million Australians.
